ALDX
Aldeyra Therapeutics·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 0
Consensus Rating "Strong Buy"
Ample Liquidity
EPS Beats Expectation
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About ALDX
Aldeyra Therapeutics, Inc.
A biotechnology company developing novel therapies for immune-mediated diseases
131 Hartwell Avenue, Suite 320, Lexington, MA 02421
--
Aldeyra Therapeutics, Inc., was incorporated in Delaware on August 13, 2004 as Neuron Systems, Inc. The company is a biotechnology company focused on developing products to treat immune-mediated, inflammatory, orphan, and diseases believed to be associated with a naturally toxic chemical species called free aldehydes. Aldeyra Therapeutics is developing next-generation drugs to improve the lives of patients with immune-mediated diseases. Aldeyra's lead product candidate, reproxalap, is a first-in-class treatment for late-developed forms of dry eye and ocular inflammation. Aldeyra is also developing product candidates for autoimmune diseases, post-transplant lymphoproliferative diseases, retinal inflammation, metabolic diseases and cancer. None of Aldeyra's product candidates are approved in the United States.
Company Financials
EPS
ALDX has released its 2025 Q3 earnings. EPS was reported at -0.13, versus the expected -0.16, beating expectations. The chart below visualizes how ALDX has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
